IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a control Closed private placement for net proceeds of $11.
Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...
Truist raised the firm’s price target on Arcellx (ACLX) to $136 from $87 and keeps a Buy rating on the shares after its Q3 results. The ...
The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.
The study – which tested Carvykti in patients with one to three lines of prior therapy – gives J&J an opportunity to leapfrog Bristol-Myers Squibb and 2Seventy bio's rival BCMA CAR-T therapy ...
Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...
GlobalData on MSN1mon
Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trialJohnson & Johnson has reported data from the Phase III CARTITUDE-4 clinical trial where CARVYKTI (ciltacabtagene autoleucel ...
In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI ®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of ...
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
Their CARVYKTI therapy, which targets BCMA, has been approved by both the FDA and European Commission, and is expanding its reach globally. This development highlights potential growth ...
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other ...
Legend Biotech Corp (NASDAQ:LEGN), a biopharmaceutical company specializing in novel cell therapies for oncology, has been making waves in the healthcare sector with its flagship product, Carvykti.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback